An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Toripalimab in Patients With Advanced HCC and Other Solid Tumors
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Porustobart (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Liver cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Harbour BioMed
- 06 Jun 2023 Results (n=44) of a phase Ib study that evaluated porustobart plus toripalimab in patients with hepatocellular carcinoma (HCC) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 May 2023 According to a Harbour BioMed media release, as of 9 December 2022, 28 patients had been dosed.
- 26 May 2023 According to a Harbour BioMed media release, the results of 1b dose expansion study were released at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.